2021
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II)
Jackson LR, Schrader P, Thomas L, Steinberg BA, Blanco R, Allen LA, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP. Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal Of Cardiovascular Drugs 2021, 21: 553-561. PMID: 33786798, DOI: 10.1007/s40256-021-00473-x.Peer-Reviewed Original ResearchConceptsModerate chronic kidney diseaseChronic kidney diseaseAtrial fibrillationRoutine clinical practiceClinical practiceInappropriate dosingOral anticoagulantsKidney diseaseConclusionIn routine clinical practiceMedian CHA2DS2VASc scoreComorbid medical conditionsDirect oral anticoagulantsUS clinical practiceBetter Informed TreatmentCockcroft-Gault formulaOne-thirdML/minCrCl 30CHA2DS2VASc scoreCreatinine clearanceRenal functionMedian ageDosage adjustmentOutcomes RegistryPrescribed doses
2020
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation
Inohara T, Holmes DN, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Hylek EM, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart 2020, 106: heartjnl-2019-315792. PMID: 31911503, DOI: 10.1136/heartjnl-2019-315792.Peer-Reviewed Original ResearchConceptsAtrial fibrillationRenal functionOral anticoagulationDose reductionAtrial Fibrillation II registryBetter Informed TreatmentML/minCrCl declineOral anticoagulantsCreatinine clearanceOutcomes RegistryGuideline criteriaPatientsPackage insertsUS FoodDrug AdministrationMean declineInformed TreatmentNOACsAnticoagulationFibrillationRegistryDosingCrClOne-fourth
2018
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF. Journal Of The American Heart Association 2018, 7: e008928. PMID: 30371218, PMCID: PMC6222961, DOI: 10.1161/jaha.118.008928.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationDabigatranDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRegistriesRenal Insufficiency, ChronicRisk FactorsStrokeTime FactorsTreatment OutcomeWarfarinConceptsBackground Chronic kidney diseaseAntiarrhythmic drug useTransient ischemic attackChronic kidney diseaseAtrial fibrillationAdvanced CKDCKD statusIschemic attackSystemic embolismCause mortalityCreatinine clearanceRhythm controlKidney diseaseDrug useAtrial fibrillation scoreBaseline renal functionOral anticoagulant useRhythm control strategyCox proportional hazardsCKD patientsMajor bleedingOAC useCardiovascular deathCKD stageHigher CHA